Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls

Table 1 Concentration of tumor M₂-PK and common clinical status in 54 patients with gastric cancer

No.	Tumor M2-PKstage (U/mL)	TNM	Metastasis	No.	Tumor M2-PK (U/mL)	TNM stage	Metastasis
1	9.26	II	N	28	24.52	IIIB	M
2	36.5	IIIA	N	29	16.6	II	M
3	23.08	II	N	30	9.26	II	N
4	23.08	IIIB	M	31	37.85	IA	N
5	165.3	IIIA	M	32	17.06	II	N
6	18.06	II	N	33	34.81	IIIA	M
7	8.81	II	N	34	14.81	II	N
8	17.34	II	N	35	23.49	II	M
9	6.87	IB	M	36	28.25	IIIA	M
10	17.91	IIIB	M	37	12.87	II	N
11	24.07	IIIB	M	38	10.62	II	M
12	12.67	II	N	39	118.02	IV	M
13	28.4	IIIB	M	40	28.75	IIIA	N
14	56.76	IIIA	N	41	14.31	II	M
15	6.42	IIIA	M	42	32.4	II	M
16	28.7	IIIB	M	43	7.61	II	N
17	7.47	IA	N	44	12.23	IA	N
18	13.9	IIIA	M	45	18.1	II	M
19	14.5	II	M	46	25.17	IIIA	M
20	69.24	IIIB	M	47	10.63	II	N
21	12.33	IIIA	M	48	8.84	II	N
22	28.66	IIIB	M	49	19.35	IIIA	N
23	136.6	IV	M	50	41.11	II	M
24	11.36	II	N	51	11.38	IIIA	N
25	7.62	II	N	52	21.75	IIIA	M
26	17.2	IB	N	53	30.03	IIIB	M
27	11.36	IIIA	M	54	11.3	II	N

N = non metastasis, M = metastasis.

Table 2 Concentration of tumor M₂-PK and common clinical status in 54 patients with colorectal cancer

No.	Tumor M2-PKstage (U/mL)	Dukes stage	Metastasis	No.	Tumor M2-PKstage (U/mL)	Dukes stage	Metastasis
1	16.14	A	N	28	11.35	A	N
2	14.35	A	N	29	37.86	A	M
3	21.96	A	N	30	41.3	A	M
4	9.86	B	N	31	21.5	B	N
5	28.71	B	N	32	13.6	B	N
6	16.29	A	N	33	6.42	A	N
7	29.75	C1	M	34	10.76	C1	N
8	20.93	A	N	35	15.78	A	N
9	18.83	C1	M	36	12.4	C1	N
10	14.8	C1	M	37	56.4	C1	M
11	20.93	A	N	38	76.32	A	M
12	15.09	C1	M	39	14.85	C1	N
13	113.8	C1	M	40	8.76	C1	N
14	18.55	B	N	41	22.35	B	M
15	67.02	C1	M	42	28.13	C1	M
16	20.05	B	N	43	33.46	B	M
17	20.05	A	N	44	25.78	A	N
18	17.95	C1	M	45	7.93	C1	N
19	91.7	C1	M	46	13.44	C1	N
20	20.2	B	N	47	48.66	B	M
21	29.75	C1	M	48	106.3	C1	M
22	86.16	C1	M	49	14.78	C1	N
23	53.11	C1	M	50	10.66	C1	N
24	108.75	B	N	51	23.35	B	N
25	42.19	A	N	52	30.16	A	N
26	7.72	A	N	53	6.11	A	N
27	19.26	B	N	54	9.45	B	N

N = non metastasis, M = metastasis.

Table 3 Detection of tumor M₂-PK in patients with gastrointes-tinal cancer and healthy donors

	n	Min (U/mL)	Max (U/mL)	Mean (U/mL)	Median (U/mL)	SD
Controls	20	4.62	20.73	10.965	9.43	4.774
Gastric cancer	54	6.42	165.3	26.937	17.34	30.604
Colorectal cancer	54	6.11	113.8	30.588	20.05	27.385